Novavax (NVAX) Stock Forecast & Price Target

Novavax is supported by a clearer path to recurring partnership economics, highlighted by the Sanofi collaboration, the fifth patient dosed in the EU Ph3 CIC trial on 10/28, and the related $125M milestone tied to 4Q revenue recognition and a possible $225M first U.S. commercial sale milestone later on. Its 3Q results were execution-focused, with $68M topline, $25.7M of product sales, $42.6M of licensing revenue, and $6.1M of royalties, while FY26 revenue guidance rose to $385M-$415M from $235M-$275M. Beyond the current COVID franchise, Matrix-M and the wholly owned pipeline add underappreciated optionality, with cash of $627M, or $676M with receivables, funding operations into 2029 and keeping the strategic value of partnered and internal programs compelling.

Novavax is facing a deteriorating revenue bridge as 2027 resets before new deals can fill the gap, with APA product sales rolling off, R&D reimbursement falling to about $5M, and Sanofi upfront amortization declining to under $5M versus $60M and $40M this year. The recurring base appears thinner than headline figures suggest because the $55M midpoint of 2026 Matrix-M supply includes up to $15M of one-time demand, while future upside hinges on uncertain milestones, royalties, and pipeline conversions such as the $75M technology transfer expected in 3Q27. Despite cost cuts that keep non-GAAP P&L profitability only as early as 2029, the company still depends heavily on Sanofi execution, faces clinical, regulatory, and competitive risk, and may need dilutive financing if milestones slip despite $700+M of cash and securities.